Kidney-disease-focused biotech startup Helex raises funding from BlueHill VC

BlueHill VC has invested in Hyderabad- and New York, USA-based biotech startup Helex .Founded in 2021 by Poulami Chaudhuri, Rohini Kalvakuntla and Anirudh Nishtala, Helex is focused on developing genetic medicines for high-burden diseases, particularly kidney diseases. It uses technology platforms, including a 3D genome-based drug designer called ‘Epic-Cure’ and a targeted lipid nanoparticle delivery system, to create precision therapies.